Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
Farillio is a legal tech company who provide legal solutions and answers for SME’s in an online platform. The platform will provide knowledge jargon free, using how-to video sound bites, checklists, infographics and short easy to read guides.
days to go:
Expired
investment:
£162,528
Businesses can now book meetings in pubs to discuss projects whilst enjoying food and drinks. MeetingsInn aims to satisfy the demand for companies that would prefer to hold discussions in smaller, yet livelier venues. Through their research, MeetingsInn has discovered 4,500 pubs that would be ideal locations for businesses to gather. All pubs will be audited to ensure they meet MeetingsInn's standards.
MeetingsInn generates revenue from a 10% commission of all bookings confirmed, as well as pubs that wish to advertise and have premium listings on the website. This crowdfunding round will allow MeetingsInn to list more pubs on their platform, as well as enhance their booking service to include tools and resources such as group accommodations.
days to go:
Expired
investment:
£60,960
Easily understand and manage all your insurance in one simple app, ready for the digital age. Wrisk is all about transparency and allows customers to see how much they’re currently paying for their insurance, what actions they can take to reduce their risk and purchase the insurance seamlessly from within the app. Wrisk is seeking investment to expand and cater for as many insurance needs as possible.
days to go:
Expired
investment:
£1,044,630
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors.
Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go:
Expired
investment:
£171,548
